throbber
0090-9556/98/2606-0528–535$02.00/0
`DRUG METABOLISM AND DISPOSITION
`Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
`
`Vol. 26, No. 6
`Printed in U.S.A.
`
`BIOTRANSFORMATION OF TOLTERODINE, A NEW MUSCARINIC RECEPTOR
`ANTAGONIST, IN MICE, RATS, AND DOGS
`
`STIG H. G. ANDERSSON, ANDERS LINDGREN, AND HANS POSTLIND
`
`Department of Drug Metabolism, Pharmacia & Upjohn AB
`
`(Received May 14, 1997; accepted February 3, 1998)
`
`This paper is available online at http://www.dmd.org
`
`ABSTRACT:
`
`Tolterodine is a new muscarinic receptor antagonist intended for
`the treatment of urinary urge incontinence and other symptoms
`associated with an overactive bladder. The in vivo metabolism of
`14C-labeled tolterodine was investigated in rats, mice, and dogs by
`analysis of blood and urine samples, whereas in vitro metabolism
`studies were performed by incubation of [14C]tolterodine with
`mouse, rat, dog, and human liver microsomes in the presence of
`NADPH. Tolterodine was extensively metabolized in vivo. Mice and
`dogs showed similar metabolite patterns, which correlated well
`with that observed in humans. In these species, tolterodine was
`metabolized along two different pathways, with the more impor-
`tant being the stepwise oxidation of the 5-methyl group to yield the
`5-hydroxymethyl metabolite of tolterodine and then, via the alde-
`hyde, the 5-carboxylic acid metabolite. The other pathway involved
`dealkylation of the nitrogen. In the subsequent phase II metabo-
`lism, tolterodine and the metabolites were conjugated with glucu-
`
`ronic acid to various degrees. Rats exhibited more extensive me-
`tabolism and a markedly different metabolite pattern, with
`metabolites also being formed by hydroxylation of the unsubsti-
`tuted benzene ring. In addition, a gender difference was observed,
`with male rats showing more extensive metabolism than females.
`Incubation of [14C]tolterodine with liver microsomes yielded a total
`of five metabolites with rat liver microsomes and three with mouse,
`dog, and human liver microsomes. The 5-hydroxymethyl metabo-
`lite of tolterodine and N-dealkylated tolterodine were major me-
`tabolites in all incubations, representing 83–99% of total metabo-
`lism. Although the extent of metabolism varied among species, the
`metabolic profiles were similar. However, rat liver microsomes
`also formed metabolites hydroxylated in the unsubstituted ben-
`zene ring. These results show that the metabolism of tolterodine in
`mice and dogs corresponds to that observed in humans, whereas
`rats exhibit a different metabolite pattern.
`
`[(R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-
`Tolterodine
`phenylpropanamine] is a new muscarinic receptor antagonist that was
`specifically developed for the treatment of urinary urge incontinence
`and other symptoms associated with an overactive bladder. Treatment
`of an overactive bladder is primarily based on the use of muscarinic
`receptor antagonists, e.g. propantheline, emepronium, and oxybutynin
`(Andersson, 1988; Wein et al., 1994), and oxybutynin is currently
`considered to be the drug of choice for the treatment of such symp-
`toms (Yarker et al., 1995). Although the efficacy of oxybutynin has
`been well demonstrated, the occurrence of classic antimuscarinic
`adverse events (e.g. dry mouth) often leads to discontinuation of
`treatment (Cardozo et al., 1987). Tolterodine is characterized by
`favorable tissue selectivity for the urinary bladder over salivary glands
`(Nilvebrant et al., 1997).
`The pharmacokinetic profile of tolterodine after oral administration
`to humans is characterized by rapid absorption and a terminal half-life
`of 2–3 hr. The excretion of drug-related substances in urine and feces
`was 77 and 17% of the administered dose, respectively (Brynne et al.,
`1997). After oral administration of 14C-labeled tolterodine to mice and
`dogs, approximately equal amounts of radioactivity were recovered in
`the urine and feces, whereas rats excreted 80% of the administered
`radioactivity in the feces. The terminal half-life of tolterodine was
`approximately 2 hr in these species (Kankaanranta and Påhlman,
`
`1997). In the present study, the metabolism of [14C]tolterodine was
`investigated by characterization of the biotransformation products
`formed in vivo by mice, rats, and dogs and in vitro by liver micro-
`somes from these species and humans.
`
`Materials and Methods
`
`Chemicals. [14C]Tolterodine (labeled at the benzylic methyl group) (fig. 1),
`tolterodine (PNU-200583), 5-HM1 [(R)-N,N-diisopropyl-3-(2-hydroxy-5-hy-
`droxymethylphenyl)phenylpropanamine, PNU-200577,
`labcode DD 01],
`5-CM (PNU-200579), and N-dealkylated tolterodine (PNU-200578) were syn-
`thesized at Pharmacia & Upjohn AB (Uppsala, Sweden). b-Glucuronidase
`(Escherichia coli, product no. 127051) was obtained from Boehringer Mann-
`heim (Mannheim, Germany) and arylsulfatase (Aerobacter aerogenes, product
`no. S1629) from Sigma Chemical Co. (St. Louis, MO). All other chemicals
`were of reagent grade and were obtained from usual commercial sources.
`In Vivo Experiments. Dogs. Six beagle dogs (three male and three female)
`were each administered an oral dose of 1.5 mg/kg [14C]tolterodine (4.2
`MBq/mg) and an iv dose of 1.0 mg/kg [14C]tolterodine. Blood samples were
`collected at 1 hr after the oral dose and at 20 min after the iv dose. Serum was
`prepared by allowing the blood to coagulate for 30 min, followed by centrif-
`ugation at 1200g for 10 min. Urine was collected cumulatively at 0 – 8 hr and
`8 –24 hr after administration of the oral and iv doses.
`Mice. Male and female mice (CD-1 strain) were each administered a single
`oral dose of 4 or 40 mg/kg [14C]tolterodine (4.2 MBq/mg). Blood from the
`orbital plexus was collected into heparinized tubes 15 min after drug admin-
`
`Send reprint requests to: Dr. Stig Andersson, Department of Drug Metabo-
`lism, Pharmacia & Upjohn AB, S-751 82 Uppsala, Sweden.
`
`1 Abbreviations used are: 5-HM, 5-hydroxymethyl metabolite of tolterodine;
`5-CM, 5-carboxylic acid metabolite of tolterodine.
`528
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1014 - Page 1
`
`

`
`TOLTERODINE METABOLISM IN MICE, RATS, AND DOGS
`
`529
`
`FIG. 1.Chemical structure of tolterodine.
`*, position of the radiolabel.
`
`istration. Samples from five mice in each group were pooled and centrifuged
`to prepare plasma, which was immediately stored at 220°C until analysis.
`Urine was collected in separate experiments in which mice were adminis-
`tered a single oral dose of 4 mg/kg [14C]tolterodine (0.6 MBq/mg). Animals
`were subsequently placed in individual metabolism cages and urine was
`collected at 0 – 6 hr and 6 –24 hr, in containers surrounded by solid carbon
`dioxide.
`Rats. Four Sprague-Dawley rats (two male and two female) were placed in
`individual metabolism cages and administered an oral dose of 50 mg/kg
`[14C]tolterodine (0.2 MBq/mg). Urine was collected at 0 –12 hr and 12–24 hr
`after dosing. All urine samples were stored at 220°C until analysis.
`In Vivo Sample Preparation. Urine. Dog urine was centrifuged and
`analyzed directly. Urine from mice was centrifuged, and metabolites were
`extracted by solid-phase extraction using a Supelco Visoprep SPE vacuum
`manifold and Isolute C18(EC), 1-g, 6-ml cartridges that had been sequentially
`conditioned with methanol and 20 mM ammonium acetate (pH 4.5). Urine (3
`ml) was applied, and the cartridges were washed with 2 ml of 20 mM
`ammonium acetate (pH 4.5). Metabolites were eluted with 2 ml of methanol/20
`mM ammonium acetate (pH 4.5) (80:20, v/v). The eluate was evaporated to
`dryness and then diluted in 30 ml of methanol and 270 ml of 20 mM
`ammonium acetate (pH 4.5). The extraction yield was 98 –100%.
`Hydrolysis of conjugated metabolites in rat urine was performed by incu-
`bation of urine samples (450 ml) with 450 ml of 0.1 M ammonium acetate (pH
`5.5) and either 20 ml of b-glucuronidase or 30 ml of arylsulfatase, for 16 hr at
`37°C. The hydrolyzed metabolites were extracted with Sep-Pak PLUS C8,
`125-Å, solid-phase cartridges, which were conditioned before use by the
`sequential passing of 5 ml of methanol and 5 ml of 20 mM ammonium acetate
`(pH 4.5) through the cartridges. Urine was applied, the cartridges were washed
`with 4 ml of 0.1 M ammonium acetate (pH 5.5)/methanol (95:5, v/v), and
`metabolites were eluted with 3 ml of methanol/0.1 M ammonium acetate (pH
`5.5) (50:50, v/v). The extract was evaporated to dryness and dissolved in 400
`ml of 20 mM ammonium acetate (pH 4.5) before analysis.
`Plasma and Serum. The plasma and serum samples were treated with
`acetone (2 times the sample volume) and centrifuged to precipitate proteins.
`The supernatants were transferred to new vials, and the pellets were washed
`twice with aliquots of acetone/20 mM ammonium acetate (pH 4.5) (1:1, v/v).
`The combined supernatant and pellet extract was evaporated to dryness and
`dissolved in 20 mM ammonium acetate (pH 4.5) containing 10% methanol.
`The extraction yield was 101 6 11% (mean 6 SD).
`In Vitro Experiments. Preparation of Microsomes from Mouse, Rat, and
`Dog Liver. Livers from untreated male mice (CD-1 strain), male Sprague-
`Dawley rats, and male Beagle dogs were used. The microsomal fraction was
`prepared from a 20% (w/v) liver homogenate in 0.25 M sucrose containing 1
`mM EDTA and 10 mM Tris-HCl buffer (pH 7.4). The homogenate was
`centrifuged at 20,000g for 20 min, and the resulting supernatant was then
`centrifuged at 100,000g for 60 min. The microsomal pellet was suspended in
`one half the original volume of 0.1 M potassium pyrophosphate buffer (pH 7.4)
`with 1 mM EDTA, homogenized, and centrifuged at 100,000g for 60 min. The
`resulting microsomal pellet was subsequently suspended and homogenized in
`100 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol and 0.1
`mM EDTA, to a total volume of 0.5–1 ml/g of liver. Microsomes were
`immediately stored at 270°C. During the preparation procedure, the temper-
`ature was maintained as close to 14°C as possible.
`Protein Determination. The protein content of microsomal fractions was
`determined as described by Lowry et al. (1951), using bovine serum albumin
`as the standard. The measured protein concentrations in the liver microsomes
`were as follows: mouse, 3.2 mg/ml; rat, 7.3 mg/ml; dog, 39.9 mg/ml.
`
`Human Liver Microsomes. Human liver microsomes were obtained from
`Human Biologics, Inc. (Phoenix, AZ). Microsomes were prepared from five
`frozen liver samples. Approximately equal amounts of microsomal protein
`from the samples were pooled, and the protein concentration was determined
`to be 20 mg/ml, as described by Lowry et al. (1951). Microsomes were stored
`at 270°C until use in the incubation experiments.
`Incubations. For each species, incubations were performed in triplicate. The
`incubation mixtures contained 100 mM potassium phosphate buffer (pH 7.4),
`1 mM NADPH, 50 mg of [14C]tolterodine, and 1 mg of liver microsomal
`protein, in a final volume of 1 ml. The reaction was started by the addition of
`25 ml of an aqueous solution of [14C]tolterodine, to yield a final concentration
`of 154 mM. The incubations were performed at 37°C for 60 min and were
`terminated by the addition of 1 ml of acetone. Control incubations in which
`NADPH was omitted were performed as described above. The samples were
`stored at 220°C for at least 1 hr before analysis. Before analysis, microsomal
`protein was precipitated by centrifugation at room temperature, and the acetone
`was evaporated with a stream of nitrogen at 37°C. A 200-ml aliquot of the
`remaining supernatant from each incubation was analyzed.
`Analysis. HPLC Analysis. Quantification of the in vitro incubation products
`was performed by HPLC using two LKB 2150 pumps, an LKB 2152 LC
`controller, a Beckman 171 radioisotope detector, a Beckman 110B solvent-
`diluting module, a Supelco PKB 100 (2-cm) precolumn, and a Supelco PKB
`100 (150- 3 4.5-mm) column. The mobile phase was 20 mM ammonium
`acetate (pH 4.5) in methanol. The solvent flow rate was 1 ml/min, and a
`gradient of decreasing polarity (0 min, 10% methanol; 5 min, 20% methanol;
`35 min, 45% methanol; 40 min, 100% methanol; 50 min, 100% methanol) was
`used.
`MS. Metabolic profiles and mass spectra of the metabolites in the in vivo
`samples from mice and dogs and from in vitro incubations were obtained by
`analysis by HPLC coupled to electrospray-ionization MS. The system con-
`sisted of an autosampler and a quaternary pump (HP1050; Hewlett-Packard)
`connected to a Supelco PKB 100 (2-cm) precolumn and a Supelco PKB 100
`(150- 3 4.5-mm) column. A stream splitter diverted approximately 80% of the
`flow to a UV detector (Pharmacia UV-M monitor, set at 280 nm) coupled to
`a radioactivity detector (Packard Radiomatic A525) and 20% to a triple-stage
`quadrupole mass spectrometer equipped with an electrospray-ionization inter-
`face (TSQ 700; Finnigan MAT). The solvent flow rate was set to 1 ml/min, and
`the mobile phase and gradient described above were used. Aliquots of 100 ml
`were analyzed. The sheath gas was set to 80 psi, and the electrospray voltage
`and capillary temperature were 4.5 kV and 200°C, respectively.
`Rat urine, hydrolyzed by b-glucuronidase, was fractionated by the HPLC
`method used for the in vitro samples. Collected fractions were evaporated and
`fractionated using a second HPLC system with a Zorbax SB-CN guard column
`(12.5 3 4 mm) and a Zorbax SB-CN column (150 3 4.6 mm). The gradient
`was as follows: 0 min, 10% methanol; 20 min, 50% methanol; 25 min, 100%
`methanol.
`Metabolites in the HPLC fractions of rat urine were analyzed by GC/MS, as
`trimethylsilyl derivatives, after treatment with 50 ml of N,O-bis(trimethylsi-
`lyl)trifluoroacetamide overnight. Mass spectra of the trimethylsilyl-derivatized
`metabolites were obtained using an HP5890A gas chromatograph connected to
`a TSQ 70 mass spectrometer with electron impact ionization at 70 eV. The gas
`chromatograph was equipped with a on-column injector and a DB-1 capillary
`column (15 m 3 0.32 mm; film thickness, 0.25 mm). One-microliter aliquots
`of the derivatization mixture were injected, and the column temperature was
`maintained at 110°C for 1 min after injection and then increased to 290°C in
`7 min. The mass spectrometer was scanned between 35 and 700 amu, with a
`cycle time of 0.7 sec.
`
`Results
`Dog Urine. The general appearance of the radiochromatograms,
`with respect to the relative concentrations of the metabolites, did not
`reveal any obvious intraindividual or gender differences. However,
`the total amount of radioactivity recovered in the urine samples did
`vary. Fig. 2a shows a typical radiochromatogram of urine collected at
`0 – 8 hr after a 1.5 mg/kg oral dose. The chromatogram contained
`major metabolite peaks at retention times of 15–16 min and 18 –20
`min, and minor peaks were evident at 11–13 min and 28 –30 min.
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1014 - Page 2
`
`

`
`530
`
`ANDERSSON ET AL.
`
`FIG. 2.Radiochromatograms of urine collected at 0 – 8 hr ( a) and serum
`collected at 1 hr (b) after oral administration of [14C]tolterodine (1.5 mg/kg) to
`a female dog.
`
`Electrospray-ionization MS of metabolites showed prominent peaks
`corresponding to the protonated molecular ion ([M1H]1) for each
`metabolite and was useful in distinguishing the metabolites in the
`unresolved peaks at 15–16 min and 28 –30 min. 5-HM, 5-CM, and
`N-dealkylated tolterodine metabolites were identified by comparing
`the retention times and product-ion mass spectra (obtained by colli-
`sion-induced dissociation of the [M1H]1 ions) with those of the
`corresponding reference standards (figs. 3–5). The 14C-labeled frag-
`ment ions of the metabolites appeared 2 amu larger than the nonla-
`beled fragment ions of the reference standards. The identities of most
`of the other metabolites were deduced from the fragmentation patterns
`of the product-ion mass spectra. Thus, the product-ion mass spectra of
`glucuronide conjugates contained peaks showing the loss of the gluc-
`uronide moiety (2176 amu) and intense peaks identical to those of the
`product-ion mass spectra of the corresponding aglycon. Several key
`fragments in the mass spectra of the N-dealkylated metabolites were
`identical to those of metabolites that were not dealkylated (table 1).
`The proposed molecular structures of identified metabolites are sum-
`marized in fig. 6. The most abundant peak (19.7 min) in the urinary
`metabolic profile of dog urine represented 5-CM, with its correspond-
`ing glucuronide conjugate (18.7 min). The other major peaks, at
`15–16 min, were not completely resolved and contained two metab-
`olites, 5-HM and N-dealkylated 5-CM. These major metabolites con-
`stituted approximately 70 – 80% of the total radioactivity in the urine
`samples. The peak at 12.4 min was N-dealkylated 5-HM. The unre-
`solved peaks at approximately 29 min contained intact tolterodine and
`its corresponding glucuronide conjugate. Trace amounts of 5-HM
`glucuronide and N-dealkylated tolterodine were also observed in some
`of the samples.
`The metabolite pattern in urine from dogs that had received an iv
`dose of 1 mg/kg was similar to that observed after the 1.5 mg/kg oral
`dose. However, the concentration of intact tolterodine in urine was
`much higher after iv administration.
`Dog Serum. The metabolite pattern observed in serum collected 1
`hr after oral administration of 1.5 mg/kg contained three major peaks,
`at retention times of approximately 16, 20, and 29 min (fig. 2b). The
`peak at 16 min represented 5-HM and N-dealkylated 5-CM, whereas
`the peak at 20 min represented 5-CM. These metabolites constituted
`
`FIG. 3.Product-ion mass spectra of 5-HM (a) and the corresponding synthesized
`reference standard (b).
`
`30 – 60% of the total radioactivity in serum samples. The most abun-
`dant peak (24 – 65% of total radioactivity), at a retention time of 29
`min, corresponded to intact tolterodine. The 1 mg/kg iv dose yielded
`a metabolite pattern that exhibited a higher relative concentration of
`intact tolterodine but was otherwise similar to that observed after oral
`administration.
`Mouse Urine. The major metabolites found in dog urine were also
`observed in mouse urine (fig. 7a), although the relative concentrations
`of N-dealkylated and conjugated metabolites were higher in mouse
`urine. The radiochromatogram of mouse urine collected at 0 – 6 hr
`after oral administration of 4 mg/kg [14C]tolterodine contained major
`peaks at retention times of 15–20 min, i.e. 5-CM and the correspond-
`ing glucuronide at 20 and 18 min, respectively, N-dealkylated 5-CM
`and 5-HM at 16 min, and N-dealkylated 5-HM glucuronide and a
`small amount of N-dealkylated 5-CM glucuronide at 15 min. The
`abundance of the [M1H]1 ion for N-dealkylated 5-CM glucuronide at
`490 amu was too low to allow a product-ion mass spectrum to be
`obtained (table 1).
`Mouse Plasma. The radiochromatograms for plasma samples col-
`lected from mice given the 4 mg/kg dose contained two major peaks
`(fig. 7b). The peaks with a retention time of 15–17 min contained
`three different metabolites, i.e. 5-HM, N-dealkylated 5-HM glucuro-
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1014 - Page 3
`
`

`
`TOLTERODINE METABOLISM IN MICE, RATS, AND DOGS
`
`531
`
`FIG. 4.Product-ion mass spectra of 5-CM (a) and the corresponding synthesized
`reference standard (b).
`
`nide, and N-dealkylated 5-CM. The other major peak corresponded to
`5-CM glucuronide. Minor peaks identified represented N-dealkylated
`tolterodine and the corresponding glucuronide and intact tolterodine,
`at retention times of 27, 29.5, and 30.5 min, respectively. After an oral
`dose of 40 mg/kg, the relative concentrations of the metabolites in the
`radiochromatograms were clearly different, in comparison with the
`metabolic profile after the lower dose. The concentrations of intact
`tolterodine and N-dealkylated tolterodine, together with its glucuro-
`nide conjugate, were increased more than proportional to dose, to-
`gether representing 11% of the radioactivity in plasma at the lower
`dose and 45% at the higher dose.
`Rat Urine. The metabolic profile in urine collected at 0 –12 hr from
`rats that had received an oral dose of 50 mg/kg differed from that for
`dogs and mice. In addition to small amounts of metabolites formed by
`dealkylation and oxidation of the 5-methyl group, rat urine contained
`several more-polar metabolites with short retention times (fig. 8).
`Urine was treated with either b-glucuronidase or arylsulfatase; only
`treatment with the former affected the appearance of the radiochro-
`matogram. After hydrolysis of glucuronic acid conjugates, the metab-
`olites were tentatively identified from retention times and mass spec-
`tra obtained by using GC/MS with trimethylsilyl derivatization.
`Trimethylsilyl derivatives were formed with the hydroxy and deal-
`kylated amino groups. The mass spectra contained diagnostic frag-
`
`FIG. 5.Product-ion mass spectra of N-dealkylated tolterodine (a) and the
`corresponding synthesized reference standard (b).
`
`ments of the nitrogen moiety and of the diphenyl cation from cleavage
`of the aliphatic side chain, which facilitated the determination of
`N-dealkylation and hydroxylation in the diphenyl moiety. These rat-
`specific metabolites were most likely formed by mono- and dihy-
`droxylation of the unsubstituted benzene ring. Three of the metabo-
`lites also contained a methoxy group. However, it was not possible to
`determine the exact sites of hydroxylation from these data. The key
`MS fragments and tentatively assigned metabolite structures are sum-
`marized in table 2. A gender difference was also observed, with urine
`from male rats containing relatively higher concentrations of these
`metabolites.
`In Vitro Studies. Liver microsomes from mice, rats, dogs, and
`humans converted [14C]tolterodine into several products in the pres-
`ence of NADPH. Five metabolites were detected in the radiochro-
`matograms for incubations with rat liver microsomes and three for
`those with mouse, dog, and human liver microsomes. The major
`metabolites of [14C]tolterodine were identified by comparison of their
`chromatographic retention times with those of reference standards
`and/or by MS.
`Table 3 shows the chromatographic retention times and the proton-
`ated molecular ions from the MS analyses, as well as the rates of
`formation of metabolites. N-Dealkylated tolterodine and 5-HM were
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1014 - Page 4
`
`

`
`532
`
`ANDERSSON ET AL.
`
`TABLE 1
`
`Summary of key MS fragmentation for tolterodine and its metabolites in dog and
`mouse urine after electrospray ionization and collision-induced dissociation
`
`Metabolite
`
`[M1H]1
`
`CIDa Fragments
`
`Tolterodine
`5-HM
`
`5-CM
`
`N-Dealkylated tolterodine
`N-Dealkylated 5-HM
`
`N-Dealkylated 5-CM
`
`Tolterodine glucuronide
`5-HM glucuronide
`5-CM glucuronide
`
`N-Dealkylated tolterodine
`glucuronide
`N-Dealkylated 5-HM glucuronide
`N-Dealkylated 5-CM glucuronide
`
`a CID, collision-induced dissociation.
`
`328
`344
`
`358
`
`286
`300
`
`316
`
`504
`518
`534
`
`460
`
`476
`490
`
`286, 199, 182, 149, 123, 91
`302, 225, 215, 197, 154, 133,
`105, 91
`316, 239, 229, 211, 194, 181,
`165, 153, 133, 105, 91
`199, 181, 149, 123, 91
`223, 213, 195, 177, 165, 167,
`152, 133, 105, 91
`239, 229, 211, 181, 165, 153,
`133, 105, 91
`328, 286, 199, 182, 149
`342, 233, 213, 195
`358, 316, 239, 229, 211, 179,
`153
`284, 196, 147, 119
`
`213, 167
`
`FIG. 7.Radiochromatograms of urine collected at 0 – 6 hr ( a) and plasma
`collected at 15 min (b) after oral administration of [14C]tolterodine (4 mg/kg)
`to mice.
`
`FIG. 6.Metabolic pathway of tolterodine in mice (given 4 mg/kg orally) and
`dogs (given 1.5 mg/kg orally or 1 mg/kg iv).
`
`major metabolites in all species. Although considerable interspecies
`differences in the extent of metabolism were apparent, the metabolic
`profiles were similar. In mice, 5-HM and N-dealkylated tolterodine
`represented approximately 20 and 64% of total metabolism, respec-
`tively. One minor product, N-dealkylated 5-HM, was also detected. In
`rats, three major metabolites were formed, i.e. 5-HM, didealkylated
`tolterodine, and N-dealkylated tolterodine, representing approxi-
`mately 5, 11, and 78% of total metabolism, respectively. Minor
`metabolites included a dihydroxylated product, N-dealkylated 5-HM,
`and a metabolite hydroxylated in the unsubstituted benzene ring,
`
`FIG. 8.Radiochromatogram of urine collected at 0 –12 hr after oral
`administration of [14C]tolterodine (50 mg/kg) to a rat.
`
`which together represented about 6% of total metabolism. The dihy-
`droxylated product and the product hydroxylated in the unsubstituted
`benzene ring were detected only in incubations with rat liver micro-
`somes. In dogs and humans, 5-HM represented approximately 39 and
`21% and N-dealkylated tolterodine represented approximately 47 and
`71% of total metabolism, respectively. One minor product, N-
`dealkylated 5-HM, was detected in both species.
`
`Discussion
`Tolterodine is extensively metabolized and similar metabolic pro-
`files were obtained for urine and plasma after oral and iv administra-
`tion to mice and dogs, indicating that biotransformation takes place
`predominantly in the liver. Biotransformation products were formed
`via two major pathways, i.e. oxidation of the 5-methyl group in the
`benzene ring and dealkylation of the nitrogen. Furthermore, conju-
`gates of both tolterodine and its metabolites were formed by glucu-
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1014 - Page 5
`
`

`
`TOLTERODINE METABOLISM IN MICE, RATS, AND DOGS
`
`533
`
`Summary of key MS fragmentation for trimethylsilyl derivatives of tolterodine and its metabolites in rat urine
`
`TABLE 2
`
`Metabolite
`
`M1
`
`[M215]1
`
`a
`
`b
`
`Metabolite
`
`M1
`
`[M215]1
`
`a
`
`b
`
`397
`
`382
`
`269
`
`114
`
`603
`
`588
`
`445
`
`144
`
`573
`
`558
`
`445
`
`114
`
`427
`
`412
`
`269
`
`144
`
`385
`
`370
`
`269
`
`102
`
`603
`
`588
`
`475
`
`114
`
`515
`
`500
`
`357
`
`144
`
`473
`
`458
`
`357
`
`102
`
`515
`
`500
`
`357
`
`144
`
`473
`
`458
`
`357
`
`102
`
`633
`
`618
`
`475
`
`144
`
`545
`
`530
`
`387
`
`144
`
`561
`
`546
`
`445
`
`102
`
`Petitioner Torrent Pharmaceuticals Limited - Exhibit 1014 - Page 6
`
`

`
`534
`
`ANDERSSON ET AL.
`
`TABLE 3
`
`Metabolism of tolterodine by mouse, rat, dog, and human liver microsomes
`
`Metabolite
`
`Retention Time
`
`[M1H]1
`
`Rate of Formation
`
`Mouse
`
`Rat
`
`Dog
`
`Human
`
`Dihydroxylated tolterodine
`N-Dealkylated 5-HM
`5-HM
`Hydroxylated tolterodine
`Didealkylated tolterodine
`N-Dealkylated tolterodine
`
`Data are mean 6 SD of three incubations.
`
`min
`9.0
`13.2–13.7
`16.7–17.3
`20.0–21.0
`23.5–23.8
`26.3–27.4
`
`358
`300
`342
`342
`242
`284
`
`0
`54 6 2
`203 6 19
`0
`0
`652 6 2
`
`pmol/mg protein/min
`,20
`41 6 6
`75 6 1
`48 6 5
`174 6 6
`1206 6 14
`
`0
`19 6 2
`249 6 13
`0
`0
`298 6 16
`
`0
`19 6 6
`130 6 10
`0
`0
`442 6 26
`
`ronidation. In contrast, rats also formed metabolites by oxidation of
`the unsubstituted benzene ring to form mono- and dihydroxylated
`metabolites, and the urinary metabolite pattern showed gender differ-
`ences. The major metabolites in dogs and mice, 5-CM and N-deal-
`kylated 5-CM, were not detected in rat urine. A possible cause of the
`different metabolite pattern in rats might be a metabolic switch
`resulting from the relatively high administered dose (50 mg/kg).
`However, mice given a similar dose (40 mg/kg) did not form metab-
`olites by oxidation of the unsubstituted benzene ring. The metabolites
`containing vicinal diols were also methylated. Methylation is not
`unexpected and occurs mainly with phenols containing vicinal diols,
`e.g. catechols (Mulder, 1982) and metabolites of terodiline (Nore´n et
`al., 1985). Terodiline has a molecular structure similar to that of
`tolterodine. Extensive metabolism and a gender difference are well
`documented in rats (Shapiro et al., 1995). In connection with toxico-
`logical studies, rats are a well-researched species and are often used as
`a primary species in preclinical safety evaluations during drug devel-
`opment. However, rats can be a poor choice in some situations. One
`such case is when rats metabolize and excrete the drug so extensively
`that relevant systemic levels of intact drug are difficult to maintain
`during toxicological studies. Another case is when the metabolite
`pattern in blood does not reflect that of humans as a result of more
`extensive metabolism; consequently, rats are not properly exposed to
`the drug and/or active metabolites, as are human subjects. General
`pharmacokinetic studies in rats have indeed shown that the systemic
`levels of tolterodine are very low, considering the administered dose
`(Kankaanranta and Påhlman, 1997). Furthermore, as a result of the
`different metabolic profile in rats, systemic levels of the pharmaco-
`logically active metabolite 5-HM are also very low. Rats were there-
`fore excluded as a main species in the preclinical safety evaluation of
`tolterodine.
`The metabolic profiles of mice and dogs showed similarities to
`those of human subjects (Brynne et al., 1997), and the major metab-
`olites in the urine from these species were 5-CM and N-dealkylated
`5-CM. The only phase II metabolites that were identified were gluc-
`uronide conjugates, and the concentrations of these were highest in
`mice. At higher doses in mice, the relative concentrations of intact
`tolterodine and N-dealkylated tolterodine were increased, whereas the
`concentrations of 5-HM and the acid metabolites were decreased,
`indicating dose-dependent biotransformation.
`Recently, we reported that the formation of 5-HM and N-dealkyl-
`ated tolterodine in humans is catalyzed by cytochrome P450 2D6 and
`3A4, respectively (Postlind et al., 1998). Further biotransformation to
`the acid metabolites via the aldehydes is most likely catalyzed by
`alcohol and aldehyde dehydrogenases. However, the metabolic capac-
`ity of cytochrome P450 2D6 in humans is much lower, in comparison
`with the 3A4 isoenzyme (Shimada et al., 1994). A possible explana-
`tion for the altered metabolism observed with the higher oral dose in
`mice is therefore that the isoenzymes involved in the formation of
`
`5-HM and the acid metabolites were saturated. Consequently, the
`relative concentrations of tolterodine and N-dealkylated tolterodine, as
`well as their glucuronide conjugates, were increased.
`In vitro studies have become an increasingly important tool in
`pharmaceutical research (Chiu, 1993; Rodrigues, 1994). Subcellular
`fractions, slices, recombinant enzymes, and cell cultures are routinely
`used in the screening for candidate drugs, the selection of species for
`toxicological studies, and the prediction of the situation in humans.
`Although results obtained from the use of microsomes are limited, the
`data often yield a good representation of the in vivo situation, in terms
`of the major metabolic pathways in which cytochromes P450 are
`involved. Incubation of tolterodine with liver microsomes in vitro
`yielded a good qualitative prediction of in vivo metabolism, although
`the carboxylated metabolites were missing because of the lack of
`alcohol and aldehyde dehydrogenases in the microsomal system.
`Furthermore, the metabolites formed in incubations with liver micro-
`somes from mice and dogs were very similar to those observed with
`human microsomes, which is in accordance with the results from in
`vivo studies.
`In conclusion, the metabolism of tolterodine was extensive. Mice
`and dogs showed similar metabolite patterns, which correlated with
`that observed for humans. Tolterodine was metabolized along two
`different pathways in these species, with the more important being the
`stepwise oxidation of the 5-methyl group attached to the benzene ring
`to yield 5-HM and then, via the aldehyde, 5-CM. The other pathway
`involved dealkylation of the nitrogen. In the subsequent phase II
`metabolism, tolterodine and the metabolites were conjugated with
`glucuronic acid to various degrees. Rats exhibited a different meta-
`bolic profile, with metabolites also being formed by hydroxylation in
`the unsubstituted benzene ring of the tolterodine molecule.
`
`References
`
`Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs
`35:477– 498.
`Brynne N, Stahl MMS, Halle´n B, Edlund PO, Palme´r L, Ho¨glund P and Gabrielsson J (1997)
`Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment
`of urinary bladder overactivity. Int J Clin Pharmacol Ther 35:287–295.
`Cardozo LD, Cooper D and Versi E (1987) Oxybutynin chloride in the management of idiopathic
`detrusor instability. Neurourol Urodyn 6:256 –257.
`Chiu SHL (1993) The use of in vitro metabolism studies in the understanding of new drugs.
`J Pharmacol Toxicol Methods 29:77– 83.
`Kankaanranta S and Påhlman I (1997) Interspecies relationship of pharmacokinetics of toltero-
`dine and prediction in man using allometric scaling. ISSX Proc 11:122.
`Lowry OH, Rosebrough NJ, Farr AL and Randall AJ (1951) Protein measurement with the Folin
`phenol reagent. J Biol Chem 193:265–275.
`Mulder GJ (1982) Conjugation of phenols, in Metabolic Basis of Detoxication (Jacoby WB, Bend
`JR and Caldwell J eds) pp 248 –264, Academic Press, New York.
`Nilv

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket